Circulating Tumor DNA in Large B-cell Lymphoma: Bridging Molecular Detection and Clinical Practice

Highlight

Circulating tumor DNA (ctDNA) provides a sensitive method to detect measurable residual disease (MRD) in large B-cell lymphoma (LBCL) patients post-therapy, potentially improving relapse risk stratification beyond standard positron emission tomography (PET) imaging. While PET remains central to response assessment, it lacks the ability to identify molecular-only residual disease that ctDNA can reveal. Clinical implementation of ctDNA-based MRD monitoring is promising but requires further validation and standardized protocols to optimize its impact on therapeutic decision-making.

Study Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply